baltic states pharma market overview · •introduction •general overview • sales dynamics in...
TRANSCRIPT
BALTIC STATES PHARMA MARKET OVERVIEW
Secondary sales analysis
Content
• Introduction
• General overview• Sales dynamics in Baltic states 2009 – 2014• Generic / Originator drugs market share in Baltic states 2013 1Q-3Q• Rx and OTC dispensing types drugs market
in Baltic states, Lithuania, Latvia and Estonia 2009 - 2014• Hospitals and pharmacies segments market share• Hospital segment Generic/ Originator medicine market share• Pharmacy segment Generic/ Originator medicine market share
• TOP 10 Producers• Lithuanian pharmacy and hospital market 2012 1Q – 2013 3Q• Latvian pharmacy and hospital market 2012 1Q – 2013 3Q• Estonian pharmacy and hospital market 2012 1Q – 2013 2Q
• TOP 5 ATC3 categories• Lithuanian pharmacy and hospital market 2012 1Q – 2013 3Q• Latvian pharmacy and hospital market 2012 1Q – 2013 3Q• Estonian pharmacy and hospital market 2012 1Q – 2013 2Q
2
Meaning of abbreviation
Volume – measure of sales quantity;
Value – wholesales amount in Euros;
CAGR – Compound Annual Growth Rate refers to the year-over-year average growth rate of an measured event over a specified period of time;
YoY – Year-over-year comparison method of evaluating two or more measured events to compare the results at one time period with those from another time period (or series of time periods), on an annualized basis;
YTD – year to date refers to measured event characteristics in time period beginning of January 1st to today’s date or specified date;
MS – market share.
3
Introduction
The following analysis are based on Lithuania, Latvia and Estonia pharmaceutical market secondary sales (wholesales) data collected by PharmaZOOM project developed by SoftDent.
Analysis period includes:
• 2009 – 2013 3Q in Latvia and Lithuania
• 2009 – 2013 2Q in Estonia
Type of medicines are restricted to OTC and Rx (Food supplements and medicine supplies are not included).
4
General overview
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
5
LT
LV
EE
Estimate
Growth
Sales dynamics in Baltic states 2009 – 2014
74 mln 72 mln 71 mln 70 mln
54 mln
19 mln
75 mln
45 mln 45 mln 43 mln 43 mln 34 mln
12 mln
47 mln
24 mln 24 mln 25 mln 26 mln 14 mln
14 mln28 mln
396 mln EUR
387 mln EUR
399 mln EUR
415 mln EUR 324 mln
EUR
121 mln EUR
466 mln EUR
233 mln EUR
236 mln EUR
236 mln EUR
242 mln EUR
186 mln EUR
65 mln EUR
258 mln EUR
182 mln EUR
186 mln EUR
198 mln EUR
219 mln EUR
115 mln EUR
115 mln EUR
244 mln EUR
0
100
200
300
400
500
600
700
800
900
1000
0
20
40
60
80
100
120
140
160
2009 2010 2011 2012 2013 2014 2009 2010 2011 2012 2013 2014
Volume Value
5,29%
1,67%2,97%
4,16%
7,22%4,75%
1,15%
6,38%
2,85%0,93% 0,11%
2,71%
3,61%
2,61%3,65%5,58%
3,86% 3,68% 2,50%
6,22%
10,85%
4,87%6,24%
-2,91%-1,07% -1,90% -2,16%
-0,24%
-4,82%
General overview
2,19% 6,10% 4,12% 0,20% 0,89% 0,83% 1,40% 0,69% 0,17%0,01% 0,49% 0,08% 1,09% 0,45% 0,98% 0,15% 0,49% 1,04% 3,66% 3,82% 5,81% 1,55% 0,45% 2,65%
-0,04% -1,80% -0,15% -1,87% -1,58% -1,73% -0,42% -1,73% -1,89% -2,42% -3,02% -2,90% -1,09% -0,33% -2,19%-0,74% -1,62% -1,43% -0,24% -1,63% -0,99% -2,64% -0,95% -0,34%
6
Originator
Generic
Originator market share growth YoY
Generic / Originator drugs market sharein Baltic states 2013 1Q-3Q
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
25% 25% 26% 27% 27%
60% 59% 58% 58% 58%
21% 21% 22% 22% 21%
56% 54% 54% 55% 54%
37% 37% 36% 35% 35%
67% 65% 65% 66% 66%
75% 75% 74% 73% 73%
40% 41% 42% 42% 42%
79% 79% 78% 78% 79%
44% 46% 46% 45% 46%
63% 63% 64% 65% 65%
33% 35% 35% 34% 34%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE
2009 2010 2011 2012 2013 2009 2010 2011 2012 2013
Volume Value
Generic market share growth YoY
General overview
7
Rx and OTC dispensing types drugs marketin Baltic states 2009 - 2014
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
665 mln EUR 666 mln EUR 685 mln EUR726 mln EUR
512 mln EUR
247 mln EUR
790 mln EUR
146 mln EUR 143 mln EUR147 mln EUR
150 mln EUR 114 mln EUR
54 mln EUR178 mln EUR
0
100
200
300
400
500
600
700
800
900
1.000
2009 2010 2011 2012 2013 2014
VA
LUE
mln
EUR
Rx Rx OTC OTC Trend Rx Trend OTC
0,10%2,95%
5,97%4,45% 4,17%
2,57% 2,37%
11,48%
6,50%
-1,72%
General overview
8
330 mln EUR 323 mln EUR 330 mln EUR 345 mln EUR
268 mln EUR
100 mln EUR
384 mln EUR
66 mln EUR 64 mln EUR68 mln EUR
70 mln EUR56 mln EUR
22 mln EUR83 mln EUR
0
50
100
150
200
250
300
350
400
450
500
2009 2010 2011 2012 2013 2014
VA
LUE,
mln
EUR
Rx Rx OTC OTC Trend Rx Trend OTC
Rx and OTC dispensing types drugs marketin Lithuania 2009 - 2014
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
2,19%
4,46%6,51%
4,38%
6,89%
2,70%
10,68%6,55%
-2,06%-2,64%
General overview
9
Rx and OTC dispensing types drugs marketin Latvia 2009 - 2014
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
179 mln EUR 181 mln EUR 184 mln EUR 191 mln EUR
144 mln EUR
49 mln EUR
197 mln EUR
54 mln EUR 54 mln EUR 52 mln EUR52 mln EUR 42 mln EUR
16 mln EUR
61 mln EUR
0
50
100
150
200
250
300
2009 2010 2011 2012 2013 2014
VA
LUE,
mln
EUR
Rx Rx OTC OTC Trend Rx Trend OTC
1,37% 1,22%
3,78%1,45% 2,00%
11,84%
5,14%
-0,52%
-3,60%
-1,06%
General overview
10
Rx and OTC dispensing types drugs marketin Estonia 2009 - 2014
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
156 mln EUR 161 mln EUR172 mln EUR
191 mln EUR
100 mln EUR
98 mln EUR
210 mln EUR
26 mln EUR25 mln EUR
26 mln EUR
29 mln EUR 16 mln EUR
17 mln EUR35 mln EUR
0
50
100
150
200
250
2009 2010 2011 2012 2013 2014
VA
LUE,
mln
EUR
Rx Rx OTC OTC Trend Rx Trend OTC
3,22%
6,43%
11,25%
3,72%5,88%4,89%
8,27%12,81% 8,85%
-1,89%
General overview
11
Hospitals and pharmacies segmentsmarket share
20% 21% 26% 28% 28%
6% 7% 6% 6% 5% 8% 9% 11% 9% 7%
80% 79% 74% 72% 72%
94% 93% 94% 94% 95% 92% 91% 89% 91% 93%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Mar
ket
shar
e b
y
VA
LUE
8% 9% 10% 10% 9% 4% 4% 4% 5% 5% 9% 8% 7% 5% 5%
92% 91% 90% 90% 91% 96% 96% 96% 95% 95% 91% 92% 93% 95% 95%
0%
20%
40%
60%
80%
100%
2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013
Estonia Latvia Lithuania
Mar
ket
shar
e b
y
VO
LUM
E
HospitalPharmacies
182 186 198 219115
233 236 236 242 186
396 387 399 415324118
62
111
0
100
200
300
400
2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013
Estonia Latvia Lithuania
Tota
l sal
es
VA
LUE
mln
EUR
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
General overview
76% 74% 77% 80% 79%66% 66% 63% 56% 53%
69% 70% 72% 66% 61%
24% 26% 23% 20% 21%34% 34% 37% 44% 47%
31% 30% 28% 34% 39%
0%
20%
40%
60%
80%
100%
Mar
ket
shar
e b
y
VA
LUE
12
Hospital segment Generic/Originator medicine market share
36 4051
62
33
15 16 15 14 9
32 3445
3823
33
6
17
0
10
20
30
40
50
60
70
2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013
Estonia Latvia Lithuania
Ho
spit
al s
ales
VA
LUE
mln
EUR
39% 41% 47% 44% 41%24% 27% 24%
17% 13% 11% 12% 14% 18% 19%
61% 59% 53% 56% 59%76% 73% 76%
83% 87% 89% 88% 86% 82% 81%
0%
20%
40%
60%
80%
100%
2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013
Estonia Latvia Lithuania
Mar
ket
shar
e b
y
VO
LUM
E
Originator
Generic
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
General overview
64% 62% 61% 61% 61% 55% 53% 54% 55% 54% 59% 58% 56% 57% 58%
36% 38% 39% 39% 39% 45% 47% 46% 45% 46% 41% 42% 44% 43% 42%
0%
20%
40%
60%
80%
100%
Mar
ket
shar
e b
y
VA
LUE
37% 36% 35% 35% 34%21% 21% 22% 22% 22% 27% 26% 27% 27% 27%
63% 64% 65% 65% 66%79% 79% 78% 78% 78% 73% 74% 73% 73% 73%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013
Estonia Latvia Lithuania
Mar
ket
shar
e b
y
VO
LUM
E
Originator
Generic
13
Pharmacy segment Generic/Originator medicine market share
145 146 147 15883
219 219 221 228177
364 353 353 377301
85
57
95
0
100
200
300
400
2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013
Ph
arm
acy
sale
s
VA
LUE
mln
EUR
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
TOP 10 corporations by sales value
HO
SPIT
AL
PR
OD
UC
ERS
Rank 2013 (2012) Corporation Sales, k € 2012Sales, k € 2013 1Q-3Q
Growth YoY2013 1Q-3Q CAGR 2010-2012
Market share (value) 2012
Market share (value) 2013
1 (4) Fresenius 2.542 1.966 5,71% 6,23% 7,37% 8,64%
2 (1) Valeant 3.852 1.846 -43,58% 65,37% 12,96% 8,11%
3 (6) Takeda 1.676 1.371 10,78% 21,81% 4,90% 6,02%
4 (10) Johnson & Johnson 1.340 1.208 1063,53% 12,59% 0,41% 5,31%
5 (3) Abbott 2.871 1.138 1,06% 11,26% 4,46% 5,00%
6 (8) GlaxoSmithKline 1.398 1.093 5,72% -2,31% 4,10% 4,80%
7 (12) Octapharma 1.224 1.086 15,69% 187,00% 3,72% 4,77%
8 (11) Sandoz 1.256 1.046 9,75% -12,32% 3,77% 4,59%
9 (5) Bayer 2.043 970 -40,28% 5,62% 6,43% 4,26%
10 (7) Genzyme 1.500 959 -18,28% -0,74% 4,65% 4,21%
TOP 1-10 19.702 12.683 -4,80% 17,69% 52,78% 55,70%
TOP 11-20 10.655 5.508 -15,67% 5,89% 25,87% 24,19%
Other 7.225 4.579 -15,03% -11,60% 21,35% 20,11%
Total 37.581 22.770 -9,79% 4,98% 100,00% 100,00%
PH
AR
MA
CY
PR
OD
UC
ERS 1 (1) Berlin Chemie 28.305 22.040 5,93% -2,20% 7,52% 7,32%
2 (2) Servier 24.488 18.854 3,16% 7,44% 6,60% 6,27%
3 (6) Pfizer 18.439 16.491 28,81% -1,17% 4,63% 5,48%
4 (5) GlaxoSmithKline 19.384 16.092 13,06% -6,37% 5,14% 5,35%
5 (3) Sanofi-Aventis 20.714 15.009 -3,13% -2,97% 5,60% 4,99%
6 (4) KRKA 20.583 14.174 -6,60% 11,73% 5,48% 4,71%
7 (10) Novartis 12.395 13.628 72,95% 23,83% 2,85% 4,53%
8 (9) Teva 14.475 11.893 12,29% -1,88% 3,83% 3,95%
9 (8) Sandoz 14.606 11.819 10,39% 6,30% 3,87% 3,93%
10 (7) AstraZeneca 14.656 11.243 4,30% 0,57% 3,90% 3,74%
TOP 1-10 188.044 151.242 10,60% -0,08% 49,42% 50,26%
TOP 11-20 84.667 69.459 10,92% 0,55% 22,63% 23,08%
Other 104.782 80.228 3,73% 4,33% 27,95% 26,66%
Total 377.493 300.928 8,76% 3,42% 100,00% 100,00%
14
Lithuanian pharmacy and hospital market 2012 1Q – 2013 3Q
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
HO
SPIT
AL
PR
OD
UC
ERS
Rank 2013 (2012) Corporation Sales, k € 2012Sales, k € 2013 1Q-3Q
Growth YoY2013 1Q-3Q CAGR 2010-2012
Market share (value) 2012
Market share (value) 2013
1 (1) Takeda 1.856 1.437 8,99% -16,22% 12,13% 15,82%
2 (7) Fresenius Kabi 674 583 28,04% 64,94% 4,18% 6,41%
3 (2) Pfizer 1.132 578 -36,91% 0,10% 8,43% 6,36%
4 (4) Sanofi-Aventis 839 571 -14,05% -1,32% 6,11% 6,29%
5 (3) Teva 1.001 529 -29,52% 26,26% 6,90% 5,83%
6 (6) Sopharma 724 467 -11,86% 11,66% 4,87% 5,14%
7 (9) Abbott 547 442 6,94% -21,94% 3,80% 4,86%
8 (8) Medochemie 548 384 -3,26% -0,74% 3,65% 4,23%
9 (20) mn pharmaceuticals 227 275 63,03% 142,78% 1,55% 3,03%
10 (16) Boehringer Ingelheim 307 265 33,03% -9,79% 1,83% 2,91%
TOP 1-10 7.855 5.530 -4,85% 4,34% 53,46% 60,90%
TOP 11-20 2.925 2.018 -8,22% 8,89% 20,22% 22,22%
Other 3.472 1.534 -46,39% -14,77% 26,31% 16,89%
Total 14.252 9.081 -16,46% -6,57% 100,00% 100,00%
PH
AR
MA
CY
PR
OD
UC
ERS 1 (2) Servier 11.803 9.012 -0,16% 8,42% 5,34% 5,08%
2 (3) Sanofi-Aventis 11.484 8.865 3,68% -2,92% 5,06% 5,00%
3 (6) Novartis 9.814 8.115 11,66% 12,07% 4,30% 4,57%
4 (1) Pfizer 11.956 8.078 -12,09% -0,68% 5,43% 4,55%
5 (5) Teva 9.977 7.505 2,93% 6,22% 4,31% 4,23%
6 (8) Merck Sharp & Dohme 8.565 7.475 20,79% 6,33% 3,66% 4,21%
7 (4) Hoffmannn-La Roche 11.293 7.340 -16,91% 34,33% 5,23% 4,14%
8 (7) GlaxoSmithKline 9.745 7.237 -0,83% -6,05% 4,32% 4,08%
9 (9) Berlin Chemie 8.253 6.583 7,90% -8,84% 3,61% 3,71%
10 (10) KRKA 7.564 6.160 11,11% 7,02% 3,28% 3,47%
TOP 1-10 100.454 76.372 1,43% 1,62% 44,53% 43,05%
TOP 11-20 59.921 47.502 7,78% 3,26% 26,07% 26,78%
Other 67.636 53.514 7,66% -0,42% 29,40% 30,17%
Total 228.010 177.389 4,92% 1,97% 100,00% 100,00%
15
TOP 10 corporations by sales value
Latvian pharmacy and hospital market 2012 1Q – 2013 3Q
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
TOP 10 corporations by sales value
HO
SPIT
AL
PR
OD
UC
ERS
Rank 2013 (2012) Corporation Sales, k € 2012Sales, k € 2013 1Q-3Q
Growth YoY2013 1Q-3Q CAGR 2010-2012
Market share (value) 2012
Market share (value) 2013
1 (1) Hoffmann-La Roche 11.577 6.128 3,41% 20,34% 18,95% 18,65%
2 (2) Abbott 5.344 2.922 5,16% 55,21% 8,89% 8,89%
3 (4) Johnson & Johnson UAB 4.002 2.528 19,96% 63,23% 6,74% 7,69%
4 (3) ViiV Healthcare UK Limited 4.549 1.628 -28,75% 2898,21% 7,31% 4,95%
5 (6) Pfizer 3.016 1.592 4,12% 1,47% 4,89% 4,84%
6 (5) Octapharma (IP) Limited 3.096 1.543 23,94% 38,27% 3,98% 4,70%
7 (7) GE Healthcare AS 2.478 1.365 8,46% 23,04% 4,02% 4,15%
8 (8) Merck Sharp & Dohme 2.154 1.032 0,85% 23,61% 3,27% 3,14%
9 (12) Baxter AG 1.374 970 47,80% -2,49% 2,10% 2,95%
10 (14) Genzyme Corp. 1.354 945 34,87% 28,87% 2,24% 2,87%
TOP 1-10 38.945 20.652 5,86% 27,19% 62,39% 62,85%
TOP 11-20 11.697 5.963 -5,55% 5,17% 20,19% 18,15%
Other 10.893 6.246 14,68% 13,79% 17,42% 19,01%
Total 61.535 32.861 5,09% 24,22% 100,00% 100,00%
PH
AR
MA
CY
PR
OD
UC
ERS 1 (1) AstraZeneca AB 9.720 5.204 7,83% -8,24% 6,13% 6,30%
2 (2) GlaxoSmithKline 9.449 5.171 11,06% 0,55% 5,91% 6,27%
3 (3) Sandoz d.d. 9.053 4.529 -0,99% 4,49% 5,81% 5,49%
4 (4) Teva 9.024 4.462 0,17% 11,45% 5,66% 5,41%
5 (7) Takeda 7.938 4.273 9,44% 5,53% 4,96% 5,18%
6 (5) Merck Sharp & Dohme 8.370 4.188 -1,45% -1,13% 5,39% 5,07%
7 (6) Novartis Pharma 8.144 4.142 -0,31% 8,34% 5,27% 5,02%
8 (8) Sanofi Aventis 7.828 3.997 3,49% -2,74% 4,90% 4,84%
9 (10) Berlin-Chemie AG (Menarini Group) 6.381 3.434 11,07% 2,79% 3,92% 4,16%
10 (11) Bayer 6.152 3.429 15,07% 10,78% 3,78% 4,15%
TOP 1-10 82.059 42.828 5,09% 1,11% 51,74% 51,89%
TOP 11-20 41.029 20.959 1,84% 4,24% 26,13% 25,39%
Other 34.783 18.746 7,50% 5,26% 22,14% 22,71%
Total 157.872 82.533 4,77% 3,82% 100,00% 100,00%
16
Estonian pharmacy and hospital market 2012 1Q – 2013 2Q
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
TOP 5 ATC3 categories
17
RANK 2013 (2012) ATCSales, k € 2013 1Q-3Q
Growth YoY 2013 1Q-3Q
Market share by value 2013 1Q-3Q Products TOP 3 Product Sales, k € 2013 1Q-3Q
Product Growth 2013 YoY 2013 1Q-3Q
HO
SPIT
AL
ATC
CA
TEG
OR
IES
1 (1) V08A 1916 -16,24% 8,42% Omnipaque 772 -12,96%
Ultravist 732 -37,85%
Visipaque 398 112,33%
2 (2) J05A 1517 -21,02% 6,66% Reyataz 668 -25,32%
Baraclude 91 -41,44%
Kaletra caps. 202 -45,05%
3 (3) B01A 1207 -11,81% 5,30% Clexane 104 -62,41%
Zibor 158 33,40%
Fraxiparine 551 16,99%
4 (7) J01D 1183 5,80% 5,20% Axetine 145 -22,49%
Reflin 127 -26,41%
Zepilen 196 18,34%
5 (5) B05X 1176 -4,88% 5,16% Natrio chloridas Fresenius 842 -0,52%
Sodium Chloride Braun 90 -42,44%
Magnio sulfatas Sanitas 114 7,55%
PH
AR
MA
CY
ATC
CA
TEG
OR
IES
1 (2) M01A 12867 12,93% 4,28% Arcoxia 948 71,45%
Nimesil 1580 13,46%
Ibumetin Nycomed 1163 17,97%
2 (1) L03A 11673 -2,36% 3,88% Pegasys 2056 15,39%
Copaxone 1703 -11,48%
Rebif 2505 -4,62%
3 (3) R03A 11250 2,06% 3,74% Symbicort 4644 6,95%
Seretide 4564 -2,62%
Berodual 595 -11,89%
4 (5) A10A 10412 4,89% 3,46% Lantus SoloStar 1820 14,46%
NovoMix 2725 -0,69%
Humalog Mix 2104 5,01%
5 (4) C09B 10307 1,43% 3,43% Presteram 2684 9,81%
Noliterax 1727 11,60%
Noliprel 1726 -11,28%
Lithuanian pharmacy and hospital market 2012 1Q – 2013 3Q
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
TOP 5 ATC3 categories
18
RANK 2013 (2012) ATCSales, k € 2013 1Q-3Q
Growth YoY 2013 1Q-3Q
Market share by value 2013 1Q-3Q Products TOP 3 Product Sales, k € 2013 1Q-3Q
Product Growth 2013 YoY 2013 1Q-3Q
HO
SPIT
AL
ATC
CA
TEG
OR
IES
1 (3) V08A 1235 15,44% 12,59% Omnipaque 412 -10,03%
Visipaque 768 28,39%
Iopamigita 42 655,36%
2 (2) B01A 1033 -14,58% 10,53% Clexane 232 -26,28%
Fraxiparine 131 -15,84%
Fragmin 169 -29,74%
3 (1) G03A 727 -39,99% 7,41% Evra 196 -39,65%
Yarina 177 -40,78%
Yasminelle 354 -39,78%
4 (4) J01D 608 -6,09% 6,19% Axetine 170 -0,58%
Ceftriaxone-BCP 117 140,56%
Cefazolin-BCPP 79 -29,25%
5 (7) J01C 466 3,87% 4,75% Pamecil 57 0,03%
Tazocin 97 16,37%
Ampisid 275 63,03%
PH
AR
MA
CY
ATC
CA
TEG
OR
IES
1 (1) L03A 7709 5,18% 4,35% Neulasta 2032 1,23%
Rebif 44 1475 17,33%
Avonex 1219 0,24%
2 (2) M01A 7125 10,07% 4,02% Ibumetin 1749 11,67%
Nimesil 364 2,00%
Dicloberl 333 3,94%
3 (4) C09B 5987 0,29% 3,38% Presteram 1531 -7,96%
Noliprel Forte 692 2,33%
Noliterax 768 17,56%
4 (6) A10B 5835 15,22% 3,29% Janumet 1118 13,57%
Metforal 495 -11,97%
Competact 599 -27,20%
5 (5) A10A 5763 -2,82% 3,25% Novorapid 1111 0,90%
Novomix 763 -23,43%
Lantus 1137 24,02%
Latvian pharmacy and hospital market 2012 1Q – 2013 3Q
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
TOP 5 ATC3 categories
19
RANK 2013 (2012) ATCSales, k € 2013 1Q-2Q
Growth YoY 2013 1Q-2Q
Market share by value 2013 1Q-2Q Products TOP 3 Product Sales, k € 2013 1Q-2Q
Product Growth 2013 YoY 2013 1Q-2Q
HO
SPIT
AL
ATC
CA
TEG
OR
IES
1 (1) L04A 1455 14,18% 13,49% Enbrel 952 5,12%
Orencia 42 161,54%
Simponi 425 37,77%
2 (2) V08A 1252 9,98% 11,61% Omnipaque 204 56,52%
Ultravist 142 -8,96%
Visipaque 907 6,51%
3 (5) J05A 689 48,33% 6,39% Norvir 134 17,29%
Prezista 503 53,65%
Ziagen 10 -3,20%
4 (6) L01X 570 40,77% 5,28% Avastin 319 4,19%
Iressa 92 219,27%
Topotecan Teva 47 64,28%
5 (7) B01A 389 -2,75% 3,61% Arixtra 16 -34,51%
Clexane 293 -3,45%
Zibor 34 -4,49%
PH
AR
MA
CY
ATC
CA
TEG
OR
IES
1 (1) A10A 4314 -1,41% 5,33% Levemir Flexpen 1127 -1,86%
Novorapid Flexpen 896 1,69%
Lantus Solostar 1301 0,89%
2 (2) M01A 3799 17,59% 4,69% Ibumetin 925 50,77%
Arcoxia 445 15,55%
Glucadol 271 -12,27%
3 (3) R03A 3261 11,40% 4,03% Seretide Diskus 1106 4,50%
Symbicort Turbuhaler 1258 19,38%
Seretide Inhaler 188 13,88%
4 (4) L03A 2897 2,46% 3,58% Pegasys 696 -6,67%
Rebif 44 Mcg 366 0,00%
Copaxone 810 10,71%
5 (6) L01X 2686 13,89% 3,32% Nexavar 433 58,95%
Glivec 877 9,66%
Sutent 516 -27,04%
Estonian pharmacy and hospital market 2012 1Q – 2013 2Q
Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;
Contacts
In case you have any questions, please contact persons provided below.
Gediminas Pukys
Analyst
UAB SoftDent
Phone +370 654 29750
Email [email protected]
Jolita Kazlauskienė
Sales Manager
UAB SoftDent
Phone +370 685 81266
Email [email protected]
Thank you in advance for your feedback, comments or suggestions.
www.softdent.lt ; +370 37 424 734; 37 425 428 20